{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:25:00Z","timestamp":1779243900021,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,19]],"date-time":"2014-11-19T00:00:00Z","timestamp":1416355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.ymgmr.2014.11.007","type":"journal-article","created":{"date-parts":[[2014,11,27]],"date-time":"2014-11-27T14:32:21Z","timestamp":1417098741000},"page":"20-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-7765","authenticated-orcid":false,"given":"Katherine H.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7990-1802","authenticated-orcid":false,"given":"Yoav H.","family":"Messinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara K.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2014.11.007_bb0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s004390050641","article-title":"Incidence of the mucopolysaccharidoses in Northern Ireland","volume":"101","author":"Nelson","year":"1997","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","article-title":"The frequency of lysosomal storage diseases in The Netherlands","volume":"105","author":"Poorthius","year":"1999","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0015","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajmg.a.20314","article-title":"Incidence of the mucopolysaccharidoses in Western Australia","volume":"123A","author":"Nelson","year":"2003","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0020","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10545-005-0112-z","article-title":"Cumulative incidence rates of the mucopolysaccharidoses in Germany","volume":"28","author":"Baehner","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/jmg.19.6.401","article-title":"A clinical and genetic study of Hunter's syndrome. 1 Heterogeneity","volume":"19","author":"Young","year":"1982","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1651-2227.2007.00212.x","article-title":"A clinical study of 77 patients with mucopolysaccharidosis type II","volume":"96","author":"Schwartz","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0035","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1542\/peds.2007-1350","article-title":"Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome)","volume":"121","author":"Martin","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0040","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s00234-004-1215-1","article-title":"Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation","volume":"46","author":"Matheus","year":"2004","journal-title":"Neuroradiology"},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1651-2227.2007.00213.x","article-title":"Mucopolysaccharidosis type II: an update on mutation spectrum","volume":"96","author":"Froissart","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0050","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet Med."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet Med."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0075","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","article-title":"The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5years and older treated with intravenous idursulfase","volume":"110","author":"Barbier","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0080","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/clinchem\/38.6.803","article-title":"Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue","volume":"38","author":"De Jong","year":"1992","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/000456329403100206","article-title":"Interaction of 1,9-dimethylmethylene blue with glycosaminoglycans","volume":"31","author":"Stone","year":"1994","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genet Med."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.seminhematol.2010.01.007","article-title":"CD20-targeted therapy: the next generation of antibodies","volume":"47","author":"van Meertena","year":"2010","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0100","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1002\/art.27524","article-title":"Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I\/II study","volume":"62","author":"\u00d8stergaard","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0105","doi-asserted-by":"crossref","first-page":"228-142","DOI":"10.1053\/j.seminhematol.2012.04.010","article-title":"Bortezomib combination therapy in multiple myeloma","volume":"49","author":"Kapoor","year":"2012","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymgmr.2014.11.007_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-014-0129-1","article-title":"Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5years","volume":"9","author":"Tomanin","year":"2014","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426914000779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426914000779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:47:01Z","timestamp":1762001221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426914000779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":22,"alternative-id":["S2214426914000779"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2014.11.007","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2014.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}